Janux Therapeutics Inc (JANX)
64.90
+2.47
(+3.96%)
USD |
NASDAQ |
May 03, 15:34
Janux Therapeutics Enterprise Value: 2.881B for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 2.881B |
| May 01, 2024 | 2.662B |
| April 30, 2024 | 2.601B |
| April 29, 2024 | 2.553B |
| April 26, 2024 | 2.104B |
| April 25, 2024 | 2.089B |
| April 24, 2024 | 2.147B |
| April 23, 2024 | 2.228B |
| April 22, 2024 | 2.181B |
| April 19, 2024 | 2.171B |
| April 18, 2024 | 2.180B |
| April 17, 2024 | 2.134B |
| April 16, 2024 | 2.267B |
| April 15, 2024 | 2.335B |
| April 12, 2024 | 2.376B |
| April 11, 2024 | 2.239B |
| April 10, 2024 | 1.961B |
| April 09, 2024 | 1.724B |
| April 08, 2024 | 1.652B |
| April 05, 2024 | 1.470B |
| April 04, 2024 | 1.485B |
| April 03, 2024 | 1.533B |
| April 02, 2024 | 1.509B |
| April 01, 2024 | 1.603B |
| March 28, 2024 | 1.601B |
| Date | Value |
|---|---|
| March 27, 2024 | 1.615B |
| March 26, 2024 | 1.662B |
| March 25, 2024 | 1.646B |
| March 22, 2024 | 1.698B |
| March 21, 2024 | 1.715B |
| March 20, 2024 | 1.677B |
| March 19, 2024 | 1.652B |
| March 18, 2024 | 1.661B |
| March 15, 2024 | 1.694B |
| March 14, 2024 | 1.607B |
| March 13, 2024 | 1.718B |
| March 12, 2024 | 1.662B |
| March 11, 2024 | 1.721B |
| March 08, 2024 | 1.713B |
| March 07, 2024 | 1.754B |
| March 06, 2024 | 1.829B |
| March 05, 2024 | 1.844B |
| March 04, 2024 | 1.812B |
| March 01, 2024 | 1.861B |
| February 29, 2024 | 1.894B |
| February 28, 2024 | 1.811B |
| February 27, 2024 | 1.957B |
| February 26, 2024 | 354.38M |
| February 23, 2024 | 381.67M |
| February 22, 2024 | 331.72M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-79.73M
Minimum
Nov 09 2023
2.881B
Maximum
May 02 2024
410.35M
Average
254.99M
Median
Jun 02 2023
Enterprise Value Benchmarks
| Viking Therapeutics Inc | 7.391B |
| Equillium Inc | 14.13M |
| Minerva Neurosciences Inc | -24.48M |
| Arvinas Inc | 947.08M |
| Calidi Biotherapeutics Inc | 8.061M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -11.76M |
| Revenue (Quarterly) | 2.461M |
| Total Expenses (Quarterly) | 18.60M |
| EPS Diluted (Quarterly) | -0.24 |
| Profit Margin (Quarterly) | -477.8% |
| Earnings Yield | -2.05% |
| Normalized Earnings Yield | -2.049 |